Advertisement

International Journal of Hematology

, Volume 109, Issue 1, pp 91–97 | Cite as

Tumor long-axis diameter and SUVmax predict long-term responders in 90Y-ibritumomab tiuxetan monotherapy

  • Norifumi Tsukamoto
  • Akihiko Yokohama
  • Tetsuya Higuchi
  • Takeki Mitsui
  • Hiromi Koiso
  • Makiko Takizawa
  • Hiroaki Shimizu
  • Takuma Ishizaki
  • Morio Matsumoto
  • Kohtaro Toyama
  • Tohru Sakura
  • Hidemi Ogura
  • Takayuki Saitoh
  • Fumihiro Ishida
  • Hirokazu Murakami
  • Yoshito Tsushima
  • Hiroshi Handa
Original Article

Abstract

90Y-ibritumomab tiuxetan (90Y-IT) is widely used, but the factors responsible for its optimal treatment effects are unknown. We enrolled 34 patients with relapsed indolent lymphoma treated with 90Y-IT monotherapy at Gunma University Hospital between 2003 and 2014 in the present study. Clinical data including computed tomography and 18-Fluoro-deoxyglucose positron emission tomography were retrospectively analyzed. The overall response rate and complete response rate were 91% and 82%, respectively. The median progression-free survival (PFS) and overall survival were 32 months and not reached, respectively. In univariate analysis, tumor long-axis diameter ≤ 2.5 cm, maximum standardized uptake value (SUVmax) ≤ 6.5, localized disease, normal levels of serum soluble interleukin-2 receptor, and the number of involved nodal sites ≤ 3 immediately prior to 90Y-IT were associated with median PFS greater than 6 years. However, in multivariate analysis, only tumor long-axis diameter ≤ 2.5 cm and SUVmax ≤ 6.5 affected PFS [hazard ratio (HR) 0.130, P = 0.0021 and HR 0.283, P = 0.0311, respectively]. Patients with only one prior regimen needed less granulocyte colony-stimulating factor and platelet transfusion. Thus, 90Y-IT treatment should be considered for patients with indolent lymphoma in first relapse who have tumor long-axis diameter ≤ 2.5 cm and SUVmax ≤ 6.5.

Keywords

Indolent lymphoma 90Y-ibritumomab tiuxetan Tumor diameter FDG-PET 

Notes

Acknowledgements

This study was supported in part by a Grant-in-Aid for Scientific Research (C), and by the National Cancer Research and Development Fund (29-A-3).

Author contributions

Conception and design: NT, AY, TH. Financial support: NT. Provision of study materials or patients: All authors. Collection and assembly of data: All authors. Data analysis and interpretation: NT, TS, AY, TH. Manuscript writing: All authors. Final approval of manuscript: All authors. Accountable for all aspects of the work: All authors

Compliance with ethical standards

Conflict of interest

Authors declared that they have no conflict of interest.

References

  1. 1.
    Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23:8447–52.CrossRefGoogle Scholar
  2. 2.
    Czuczman MS, Grillo-López AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268–76.CrossRefGoogle Scholar
  3. 3.
    Watanabe T, Tobinai K, Shibata T, Tsukasaki K, Morishima Y, Maseki N, et al. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin’s lymphoma: JCOG 0203 trial. J Clin Oncol. 2011;29:3990–8.CrossRefGoogle Scholar
  4. 4.
    Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:4473–9.CrossRefGoogle Scholar
  5. 5.
    Tobinai K, Watanabe T, Ogura M, Morishima Y, Ogawa Y, Ishizawa K, et al. Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin’s lymphoma. J Clin Oncol. 2006;24:174–80.CrossRefGoogle Scholar
  6. 6.
    Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:2453–63.CrossRefGoogle Scholar
  7. 7.
    Tobinai K, Watanabe T, Ogura M, Morishima Y, Hotta T, Ishizawa K, et al. Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci. 2009;100:158–64.CrossRefGoogle Scholar
  8. 8.
    Evens AM, Vanderplas A, LaCasce AS, Crosby AL, Nademanee AP, Kaminski MS, et al. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer. 2013;119:3662–71.CrossRefGoogle Scholar
  9. 9.
    Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17:3793–803.CrossRefGoogle Scholar
  10. 10.
    Gregory SA, Hohloch K, Gisselbrecht C, Tobinai K, Dreyling M. Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin’s lymphoma. Oncologist. 2009;14(Suppl 2):4–16.CrossRefGoogle Scholar
  11. 11.
    Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.CrossRefGoogle Scholar
  12. 12.
    Tokue A, Higuchi T, Arisaka Y, Nakajima T, Tokue H, Tsushima Y. Role of F-18 FDG PET/CT in assessing IgG4-related disease with inflammation of head and neck glands. Ann Nucl Med. 2015;29:499–505.CrossRefGoogle Scholar
  13. 13.
    Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–65.CrossRefGoogle Scholar
  14. 14.
    Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555–62.CrossRefGoogle Scholar
  15. 15.
    Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007;109:1804–10.CrossRefGoogle Scholar
  16. 16.
    Uike N, Choi I, Tsuda M, Haji S, Toyoda K, Suehiro Y, et al. Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era. Int J Hematol. 2014;100:386–92.CrossRefGoogle Scholar
  17. 17.
    Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51:25–30.CrossRefGoogle Scholar
  18. 18.
    Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:4643–51.CrossRefGoogle Scholar
  19. 19.
    Morschhauser F, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani PL, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood. 2007;110:54–8.CrossRefGoogle Scholar
  20. 20.
    Ngeow JY, Quek RH, Ng DC, Hee SW, Tao M, Lim LC, et al. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma. Ann Oncol. 2009;20:1543–7.CrossRefGoogle Scholar
  21. 21.
    Novelli S, Briones J, Flotats A, Sierra J. PET/CT assessment of follicular lymphoma and high grade B cell lymphoma. Good correlation with clinical and histological features at diagnosis. Adv Clin Exp Med. 2015;24:325–30.CrossRefGoogle Scholar
  22. 22.
    Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36:1836–9.Google Scholar
  23. 23.
    Lopci E, Zanoni L, Chiti A, Fonti C, Santi I, Zinzani PL, et al. Fanti S. FDG PET/CT predictive role in follicular lymphoma. Eur J Nucl Med Mol Imaging. 2012;39:864–71.CrossRefGoogle Scholar
  24. 24.
    Kostakoglu L, Goy A, Martinelli G, Caballero D, Crump M, Gaidano G, et al. FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study. Leuk Lymphoma. 2017;58:372–81.CrossRefGoogle Scholar
  25. 25.
    Adams HJ, Nievelstein RA, Kwee TC. Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review. Ann Hematol. 2016;95:11–8.CrossRefGoogle Scholar
  26. 26.
    Meignan M, Cottereau AS, Versari A, Chartier L, Dupuis J, Boussetta S, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol. 2016;34:3618–26.CrossRefGoogle Scholar
  27. 27.
    Illidge TM, McKenzie HS, Mayes S, Bates A, Davies AJ, Pettengell R, et al. Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. Br J Haematol. 2016;173:274–82.CrossRefGoogle Scholar
  28. 28.
    Morschhauser F, Radford J, Van Hoof A, Botto B, Rohatiner AZ, Salles G, et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial. J Clin Oncol. 2013;31:1977–83.CrossRefGoogle Scholar
  29. 29.
    Casadei B, Pellegrini C, Pulsoni A, Annechini G, De Renzo A, Stefoni V, et al. 90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years. Cancer Med. 2016;5:1093–7.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  • Norifumi Tsukamoto
    • 1
    • 2
  • Akihiko Yokohama
    • 2
    • 3
  • Tetsuya Higuchi
    • 4
  • Takeki Mitsui
    • 2
  • Hiromi Koiso
    • 2
  • Makiko Takizawa
    • 2
  • Hiroaki Shimizu
    • 2
  • Takuma Ishizaki
    • 2
  • Morio Matsumoto
    • 5
  • Kohtaro Toyama
    • 6
  • Tohru Sakura
    • 7
  • Hidemi Ogura
    • 8
  • Takayuki Saitoh
    • 9
  • Fumihiro Ishida
    • 10
  • Hirokazu Murakami
    • 9
  • Yoshito Tsushima
    • 4
  • Hiroshi Handa
    • 2
  1. 1.Oncology CenterGunma University HospitalMaebashiJapan
  2. 2.Department of HematologyGunma University Graduate School of MedicineMaebashiJapan
  3. 3.Transfusion ServiceGunma University HospitalMaebashiJapan
  4. 4.Department of Diagnostic Radiology and Nuclear MedicineUniversity Graduate School of MedicineMaebashiJapan
  5. 5.Department of HematologyNational Hospital Organization Shibukawa Medical CenterShibukawaJapan
  6. 6.Division of Internal MedicineFujioka General HospitalFujiokaJapan
  7. 7.Division of Internal MedicineSaiseikai Maebashi HospitalMaebashiJapan
  8. 8.Division of Internal MedicineMaebashi Red Cross HospitalMaebashiJapan
  9. 9.Department of Laboratory SciencesGunma University Graduate School of Health SciencesMaebashiJapan
  10. 10.Department of Biomedical Laboratory MedicineShinshu University School of MedicineMatsumotoJapan

Personalised recommendations